title: Glycemic and lipidic profile in diabetic patients undergoing dialysis.
abstract: OBJECTIVE
  The aim of this study is to assess the clinical care pattern and to compare the lipid and glycemic profile in a group of diabetic patients undergoing both hemodialysis (HD) and peritoneal dialysis (PD) and to correlate these data using biomarkers of cardiovascular risk.
  
  
  METHODS
  The first phase consisted in performing a survey on demographic data, questions about the medical team and glycemic control. In the second phase, patients were assessed through laboratorial data on their glycemic and lipid profile at a single center for HD and PD.
  
  
  RESULTS
  91 patients was the total population; 70 patients (77%) answered the survey; 66 patients (94%) considered the nephrologist the physician responsible for caring for their glycemic control. Second phase: 59 patients were assessed, 29 undergoing HD and 30 undergoing PD. Fifty-seven percent of the patients had HbA1c above 7%; the level of glycemic markers in patients undergoing peritoneal dialysis was significantly higher than in patients undergoing hemodialysis: HbA1c (9.37 ± 0.5) vs. (7.37 ± 0.49) p < 0.01; fasting glycemia (170 ± 15) vs. (126 ± 15) mg/dL p < 0.05. We found a positive correlation between HbA1c and hyperfibrinogenemia (r = 0.4437, p < 0.0005).
  
  
  CONCLUSIONS
  The data reveal that glycemic control in diabetic patients undergoing renal replacement therapy (RRT) is neglected. Peritoneal dialysis is related to the worst level of glycemic markers, possibly due to the glucose content in the dialysis solution, and higher levels from HbA1c have a positive correlation with hyperfibrinogenesis in this population.
authors.affiliation: Biology and Health Sciences Center, Pontifícia Universidade Católica do Paraná, Curitiba, PR, Brazil.
authors.forename: Paulo Cezar
authors.initials: PC
authors.lastname: Fortes
authors.forename: Jamille Godoy
authors.initials: JG
authors.lastname: Mendes
authors.forename: Karoline
authors.initials: K
authors.lastname: Sesiuk
authors.forename: Letícia Barros
authors.initials: LB
authors.lastname: Marcondes
authors.forename: Carlos Alberto Mayora
authors.initials: CA
authors.lastname: Aita
authors.forename: Miguel Carlos
authors.initials: MC
authors.lastname: Riella
authors.forename: Roberto
authors.initials: R
authors.lastname: Pecoits-Filho
mesh_terms: D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000032:analysis*; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000517:prevention & control*; D003928:Diabetic Nephropathies / Q000097:blood / Q000628:therapy*; D004812:Epidemiologic Methods; D005260:Female; D005340:Fibrinogen / Q000032:analysis*; D006442:Glycated Hemoglobin / Q000032:analysis*; D006801:Humans; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010348:Patient Care Team / Q000592:standards; D010530:Peritoneal Dialysis; D006435:Renal Dialysis / Q000379:methods*
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D005340:Fibrinogen; D006442:Glycated Hemoglobin; D008055:Lipids